

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A pharmaceutical composition in the form of an extrudate obtainable by mixing
 at least one active ingredient comprising a non-micronized 17- β -estradiol or ethinylestradiol with
 at least one extrusion additive which is from a polyalcohol esterified with a fatty acid
~~wherein the extrusion additive comprises~~ a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, and
 an adjuvant comprising polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof
 and joint melt extruding.
2. **(Canceled)**
3. **(Canceled)**
4. **(Currently Amended)** A pharmaceutical composition according to claim 1, wherein the fatty acid of the sugar fatty acid ester, the polyethylene glycol fatty acid ester or the glycerol fatty acid ester has 1 to 31 carbon atoms and is ~~are~~ unbranched and/or branched and/or saturated and/or unsaturated.
5. **(Canceled)**
6. **(Previously Presented)** A pharmaceutical composition according to claim 1, wherein the melt extrusion is carried out without additional heat input.
7. **(Currently Amended)** A pharmaceutical composition according to claim

26, + wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable by mixing 17- β -estradiol, polyvinylpyrrolidone and saccharose monopalmitate and joint melt extruding at 60°C.

8. **(Currently Amended)** A pharmaceutical composition according to claim 26, + wherein the extrusion additive is glycerol tribehenate and the composition is obtainable by mixing 17- β -estradiol, polyvinylpyrrolidone and glycerol tribehenate and joint melt extruding at 60°C.

9. **(Currently Amended)** A pharmaceutical composition according to claim 26, + wherein the extrusion additive is saccharose monopalmitate and the composition is obtainable by mixing ethinylestradiol, polyvinyl-pyrrolidone and saccharose monopalmitate and joint melt extruding at 60°C.

10. **(Currently Amended)** A process for the production of a pharmaceutical composition comprising joint melt extruding a mixture comprising at least one active ingredient of non-micronized 17- β -estradiol or ethinylestradiol with at least one extrusion additive of a polyalcohol esterified with a fatty acid.

11. **(Previously Presented)** A process according to claim 10, wherein the melt extrusion is carried out without heat input.

12. **(Currently Amended)** A process according to claim 10, further comprising grinding the extruded mixture and processing the resultant granules into a pharmaceutical agent with a pharmaceutically compatible adjuvant or additive.

13. **(Previously Presented)** A pharmaceutical agent comprising a pharmaceutical composition according to claim 1 and an additional pharmaceutically compatible adjuvant or additive.

14. (Canceled)

15. (Currently Amended) A process according to claim 11, further comprising grinding the extruded mixture and processing the resultant granules into a pharmaceutical agent with a pharmaceutically compatible adjuvant or additive.

16. (Canceled)

17. (Currently Amended) A pharmaceutical composition according to claim 1, wherein the composition comprises 0.025% of said at least one active ingredient ~~relative to a single dose.~~

18. (Canceled)

19. (Currently Amended) A pharmaceutical composition according to claim 1, wherein the extrusion additive consists of a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, the at least one active ingredient consists of non-micronized 17- β -estradiol or ethinylestradiol, and the adjuvant consists of polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer, or a mixture thereof.

20. (Currently Amended) A pharmaceutical composition obtained by extruding a mixture comprising non-micronized 17- β -estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

21. (Canceled)

22. (Previously Presented) A pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a solid dispersion.

23. (Currently Amended) A mixture comprising non-micronized 17- β -estradiol or ethinylestradiol and a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

24. (Currently Amended) A pharmaceutical composition according to claim 1, further comprising an additional active ingredient selected from ~~of~~:

acebutolol, acetylcysteine, acetylsalicylic acid, aciclovir, alprazolam, albumin, alfacalcidol, allantoin, allopurinol, ambroxol, amikacin, amiloride, aminoacetic acid, amiodarone, amitriptyline, amlodipine, amoxicillin, ampicillin, ascorbic acid, aspartame, astemizole, atenolol, beclometasone, benserazide, benzalkonium hydroxide, benzocaine, benzoic acid, betamethasone, bezafibrate, biotin, biperiden, bisoprolol, bromazepam, bromhexine, bromocriptine, budesonide, bufexamac, buflomedil, buspirone, caffeine, camphor, captopril, carbamazepine, carbidopa, carboplatin, cefaclor, cefalexin, cefadroxil, cefazolin, cefixime, cefotaxime, ceftazidime, ceftriaxone, cefuroxime axetil, chloramphenicol, chlorhexidine, chloropheniramine, chlorthalidone, choline, ciclosporin, cilastatin, cimetidine, ciprofloxacin, cisapride, cisplatin, clarithromycin, clavulanic acid, clomipramine, clonazepam, clonidine, clotrimazole, clozapine, codeine, colestyramine, cromoglycic acid, cyanocobalamin, cyproterone, desogestrel, dexamethasone, dexpanthenol, dextromethorphan, dextropropoxyphene, diazepam, diclofenac, digoxin, dihydrocodeine, dihydroergotamine, diltiazem, diphenhydramine, dipyrindamole, dipyrone, disopyramide, domperidone, dopamine, enalapril, ephedrine, epinephrine, ergocalciferol, ergotamine, erythromycin, etoposide, eucalyptus globulus, famotidine, felodipine, fenofibrate, fenoterol, fentanyl, flavin mononucleotide, fluconazole, flunarizine, fluorouracil, fluoxetine, flurbiprofen, furosemide, gemfibrozil, gentamicin, ginkgo biloba, glibenclamide, glipizide, glycyrrhiza glabra, guaifenesin, haloperidol, heparin, hyaluronic acid, a hydrochlorothiazide, hydrocodone, hydrocortisone, hydromorphone, ipratropium hydroxide, ibuprofen, imipenem, indomethacin, iohexol, iopamidole, isosorbide dinitrate, isosorbide mononitrate, isotretinoin, ketotifen, ketoconazole, ketoprofen, ketorolac, labetalol, lactulose, lecithin, levocarnitine, levodopa, levoglutamide, levonorgestrel, levothyroxine, lidocaine, lipase, lisinopril, loperamide, lorazepam, lovastatin, medroxyprogesterone, menthol, methotrexate, methyl dopa, methylprednisolone, metoclopramide, metoprolol, miconazole,

midazolam, minocycline, minoxidil, misoprostol, morphine, a multivitamin, a mineral, nystatin, N-methylephedrine, naftidrofuryl, naproxen, neomycin, nicardipine, a nicergoline, nicotinamide, nicotine, nicotinic acid, nifedipine, nimodipine, nitrendipine, nizatidine, norethisterone, norfloxacin, norgestrel, nortriptyline, ofloxacin, omeprazole, ondansetron, pancreatin, panthenol, pantothenic acid, paracetamol, penicillin G, penicillin V, phenobarbital, a pentoxifylline, phenylephrine, phenylpropanolamine, phenytoin, piroxicam, polymyxin B, povidone-iodine, pravastatin, prazosin, prednisolone, propafenone, propranolol, pseudoephedrine, pyridoxine, quinidine, ramipril, ranitidine, reserpine, retinol, riboflavin, rifampicin, rutoside, saccharin, salbutamol, salcatonin, salicylic acid, selegiline, simvastatin, somatropin, sotalol, spironolactone, sucralfate, sulbactam, sulfamethoxazole, sulpiride, tamoxifen, tegafur, teprenone, terazosin, terbutaline, terfenadine, theophylline, thiamin, ticlopidine, timolol, tranexamic acid, tretinoin, triamcinolone acetonide, triamterene, trimethoprim, troxerutin, uracil, valproic acid, vancomycin, verapamil, vitamin E, volic acid, and ~~or~~ zidovudine.

25. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient comprising a non-micronized 17- β -estradiol or ethinylestradiol, at least one extrusion additive from a polyalcohol esterified with a fatty acid wherein the extrusion additive comprises a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, and an adjuvant comprising polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof.

26. (New) A pharmaceutical composition obtainable by mixing
at least one active ingredient comprising 17- β -estradiol or ethinylestradiol with
at least one extrusion additive selected from polyalcohols esterified with a fatty acid
wherein the extrusion additive comprises a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester, and
an adjuvant comprising polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof
and joint melt extruding,
wherein

- a) the extrusion additive is saccharose monopalmitate and the composition is obtainable by mixing 17- β -estradiol, polyvinylpyrrolidone and saccharose monopalmitate;
- b) the extrusion additive is glycerol tribehenate and the composition is obtainable by mixing 17- β -estradiol, polyvinylpyrrolidone and glycerol tribehenate; or
- c) the extrusion additive is saccharose monopalmitate and the composition is obtainable by mixing ethinylestradiol, polyvinyl-pyrrolidone and saccharose monopalmitate.

27. (New) A pharmaceutical composition according to claim 1, wherein the at least one extrusion additive is a sugar fatty acid ester.

28. (New) A pharmaceutical composition according to claim 1, consisting essentially of

- a) a non-micronized 17- β -estradiol or ethinylestradiol;
- b) a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester; and
- c) an polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof

29. (New) A pharmaceutical composition according to claim 1, consisting of

- a) a non-micronized 17- β -estradiol or ethinylestradiol;
- b) a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester; and
- c) an polyvinylpyrrolidone, polyethylene glycol, vinylpyrrolidonevinyl acetate copolymer or a mixture thereof

30. (New) A mixture according to claim 23 consisting essentially of

- a) non-micronized 17- β -estradiol or ethinylestradiol and
- b) a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

31. (New) A mixture according to claim 23 consisting of
a) non-micronized 17- β -estradiol or ethinylestradiol and
b) a sugar fatty acid ester, a polyethylene glycol fatty acid ester or a glycerol fatty acid ester.

32. (New) A pharmaceutical composition according to claim 1, which is in the form of a tablet.